The OPUS-1 topline success substantially de-risks VAX-31's regulatory path. Watch for OPUS-2 (concomitant influenza) and OPUS-3 (previously vaccinated adults) data in 1H 2027, which will be included in the BLA. The FDA's focus on the PCV21 comparison (where 2 serotypes missed the stringent >0.667 bar but met the historical >0.5 threshold) will be a key review point.
Price Chart
Executive Summary
Vaxcyte reported positive topline Phase 3 data from the OPUS-1 pivotal trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50+ and the primary immunobridging endpoint in adults 18-49, with a safety profile similar to Prevnar 20 (PCV20) and Capvaxive (PCV21). These results serve as the cornerstone for a planned Biologics License Application (BLA) submission in the first half of 2028, significantly de-risking the program and supporting a potential best-in-class profile.
Key Facts
- VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older: all 28 shared serotypes met noninferiority (LBCI >0.667) and all 3 unique serotypes plus cross-reactive 20B met superiority (LBCI >2.0).
- VAX-31 met the primary immunobridging endpoint: all 321 serotype OPA GMR comparisons in adults 18-49 vs 50-64 met noninferiority (LBCI >0.667).
- VAX-31 was well tolerated with a safety profile similar to PCV20 and PCV21 across all ages studied; no serious adverse events were considered related to study vaccines.
- In prespecified individual comparator analyses, VAX-31 met noninferiority (LBCI >0.667) for 20 of 20 serotypes vs PCV20 and 17 of 19 vs PCV21; serotypes 3 and 12F vs PCV21 met the historical LBCI >0.5 threshold.
- Company expects to report OPUS-2 and OPUS-3 Phase 3 topline results in the first half of 2027, supporting planned BLA submission in the first half of 2028.
- VAX-31 is designed to cover approximately 95% of IPD and 88% of pneumococcal pneumonia in U.S. adults 50+, providing an incremental 13-36% IPD and 19-31% pneumonia coverage over current standard-of-care adult PCVs.
Financial Impact
No financial figures reported in the filing. The pneumococcal vaccine market is estimated at $8.5B today, expected to grow to ~$12B by 2030 per the slide presentation.
Risk Factors
- Two serotypes (3 and 12F) missed the prespecified >0.667 noninferiority threshold vs PCV21, though met the historical >0.5 threshold — this could be a focus of FDA review.
- BLA submission is not expected until first half of 2028, leaving ~1.5 years of clinical and regulatory uncertainty.
- Manufacturing consistency study and commercial-scale readiness remain to be demonstrated.
- Competitive dynamics with PCV20 (Pfizer) and PCV21 (Merck) could impact market adoption post-approval.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-413168 |
| Document: d21202dex992.htm | 0001193125-26-413168 |
| Document: d21202d8k.htm | 0001193125-26-413168 |
| Document: 0001193125-26-413168-index-headers.html | 0001193125-26-413168 |
| Document: 0001193125-26-413168-index.html | 0001193125-26-413168 |
| Document: 0001193125-26-413168.txt | 0001193125-26-413168 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $70.65 $63.68 | ▲ +9.87% | ▲ +8.37% | $60.67 (+14.13%) |
Oct 8, 2026 19d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.67 (+15.00%) |
Oct 8, 2026 19d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.67 (+15.00%) |
Oct 5, 2026 22d ago | 424B5 | $66.70 $66.80 | ▲ +0.15% | ▲ +0.29% | $60.67 (−9.04%) |
Oct 5, 2026 22d ago | 424B5 | $66.70 $66.80 | ▼ −0.15% | ▼ −0.29% | $60.67 (+9.04%) |
Oct 5, 2026 22d ago | 8-K | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Oct 5, 2026 22d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Oct 4, 2026 23d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Aug 5, 2026 11w ago | Insider Cluster | $58.89 $58.86 | ▼ −0.05% | ▼ −1.26% | $60.67 (+3.02%) |
Jul 6, 2026 16w ago | Insider Cluster | $60.67 $56.21 | ▼ −7.35% | ▼ −7.90% | $60.67 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers